ISSN 1004-6879

CN 13-1154/R

 

承德医学院学报 ›› 2019, Vol. 36 ›› Issue (6): 468-471.

• 临床医学 • 上一篇    下一篇

重组人脑利钠肽联合硝普钠和多巴胺治疗难治性心力衰竭45例

陈新立   

  1. 洛阳市吉利区人民医院,河南洛阳 471012
  • 收稿日期:2019-07-12 出版日期:2019-12-10 发布日期:2021-11-18

CURATIVE EFFECT OF RECOMBINANT HUMAN BRAIN NATRIURETIC PEPTIDE COMBINED WITH SODIUM NITROPRUSSIDE AND DOPAMINE IN THE TREATMENT OF REFRACTORY HEART FAILURE OF 45 CASES

CHEN Xin-li   

  1. People's Hospital of Jilin District, Henan Luoyang 471012, China
  • Received:2019-07-12 Online:2019-12-10 Published:2021-11-18

摘要: 目的:探讨重组人脑利钠肽联合硝普钠、多巴胺治疗难治性心力衰竭的疗效及对心功能的影响。方法:90例难治性心力衰竭患者,随机分为对照组和观察组各45例。两组均接受常规基础用药,对照组患者同时给予硝普钠和多巴胺治疗,观察组患者同时给予重组人脑利钠肽、硝普钠和多巴胺三药联合治疗。观察两组患者的临床疗效、生命体征(血压和心率)、心功能及药物不良反应。结果:治疗后,观察组治疗有效率为55.56%,明显高于对照组的33.33%(P<0.05)。治疗后,观察组的收缩压、舒张压和心率与对照组比较,差异均无统计学意义(P>0.05)。治疗后,观察组患者氨基末端脑钠肽(NT-proBNP)水平明显低于对照组,左室射血分数(LVEF)明显高于对照组(P<0.05)。两组患者药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采用重组人脑利钠肽联合硝普钠和多巴胺治疗难治性心力衰竭疗效显著,能有效改善患者的心功能,值得临床借鉴。

关键词: 难治性心力衰竭, 重组人脑利钠肽, 硝普钠, 多巴胺, 心功能

Abstract: Objective: To explore the effects of recombinant human brain natriuretic peptide combined with sodium nitroprusside and dopamine on patients with refractory heart failure and its effects on cardiac function. Methods: 90 patients with refractory heart failure were randomly divided into control group and observation group, with 45 cases in each group. The patients in 2 groups were all given conventional basic medication; On this basis, the patients in control group were given sodium nitroprusside and dopamine, the patients in observation group were given recombinant human brain natriuretic peptide, sodium nitroprusside and dopamine. The clinical efficacy, vital signs (blood pressure and heart rate), cardiac function and adverse drug reactions of patients in 2 groups were observed. Results: After treatment, the treatment effective rate of observation group was significantly higher than control group (55.56% vs 33.33%, P<0.05). There were no significant differences in the blood pressure, heart rate and incidence of adverse drug reactions between observation group and control group after treatment (P>0.05). The level of amino-terminal pro-brain natriuretic peptide (NT-proBNP) of patients in observation group was significantly lower than control group, while the left ventricular ejection fraction (LVEF) was significantly higher (P<0.05). Conclusions: Recombinant human brain natriuretic peptide combined with sodium nitroprusside and dopamine has significant treatment effects on patients with refractory heart failure, and it can effectively improve cardiac function. So it is worthy of clinical reference.

Key words: Refractory heart failure, Recombinant human brain natriuretic peptide, Sodium nitroprusside, Dopamine, Cardiac function

中图分类号: